Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Background: Platinum-based drugs prevail as the main treatment of lung cancer; this is caused by their relative effectiveness despite known side effects, such as neurotoxicity. The risk reward of the treatment and side effects is confronted when dosage is considered and when resistance to treatment...

Full description

Bibliographic Details
Main Authors: Xixi Lin, Yongliang Jia, Xinwei Dong, Jian Shen, Yachao Jin, Yanyou Li, Fang Wang, Eitan Anenberg, Jiancang Zhou, Jianping Zhu, Xiaoping Chen, Qiangmin Xie, Yicheng Xie
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Pharmacology
Subjects:
lung cancer
platinum complex
water solubility
ROS/p53 pathway
cisplatin resistance
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00982/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00982/full

Similar Items